Q-Vant Biosciences

q-vant is a privately held company that has solved the supply chain problem of qs-21 and other quillaja-based saponin adjuvants for the global human and animal pharmaceutical markets. the company’s next-generation technology platform combines computational learning techniques with a proprietary multi-step purification process to increase the supply of qs-21 by more than 1,000 – enabling the production of billions of doses annually to meet today’s increasing global market demand. led by a team with unrivaled experience in vaccine and adjuvant development, manufacturing and global regulatory requirements, and with world-class knowledge in quillaja saponin supply chain, agronomy, extraction and purification, q-vant is the first company that is vertically integrated to combine a secured sustainable quillaja raw material supply with pharma cgmp commercial-scale production of qs-21 and other saponin-based adjuvants. for more information, visit www.q-vant.com.